AXGN
NEUTRAL
$32.83
Live
Axogen, Inc. · NASDAQ
Target $37.0
(+12.7%)
$9.22
52W Range
$34.71
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$1.51B
P/E
N/A
ROE
-1.9%
Profit margin
-1.0%
Debt/Equity
0.58
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
65%
AXGN exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, and lacks an Altman Z-Score, limiting distress risk assessment. Despite strong revenue growth of 23.5% and improving profitability trends, the company remains unprofitable on a net basis with negative ROE and no meaningful cash flow data. Valuation metrics are stretched, with a high forward P/E of 65.88 and a Price/Book of 12.53, while insider selling of $10.58M in the last six months raises caution. Analysts maintain a strong_buy recommendation, but recent earnings volatility and lack of profitability temper bullish sentiment.
Key Strengths
Strong revenue growth (23.5% YoY) outpaces sector average of 40.81% despite smaller scale
High gross margin of 74.76% reflects pricing power and low production costs
Solid balance sheet with current ratio of 4.09 and quick ratio of 2.38 indicating strong liquidity
Improving operating margin at 3.18%, showing progress toward profitability
Analyst consensus is strong_buy with a $37.00 target price, implying 12.7% upside
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health and inconsistent profitability
Negative net profit margin (-0.98%) and ROE (-1.91%) suggest ongoing earnings challenges
Lack of Altman Z-Score prevents clear assessment of bankruptcy risk
Insider selling of $10.58M in last 6 months signals bearish sentiment from leadership
High valuation with forward P/E of 65.88 and Price/Book of 12.53 makes stock vulnerable to multiple contraction
AI Fair Value Estimate
Based on comprehensive analysis
$28.5
-13.2% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
41
Moderate
40
65
55
45
0
AI Verdict
Cautiously optimistic with significant financial and valuation risks
Key drivers: Revenue growth and margin expansion, High forward valuation, Weak Piotroski score, Negative earnings quality, Bullish analyst outlook
Confidence
70%
Value
40/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 65.88 is lower than sector average of 220.68
Watchpoints
- No Graham Number or intrinsic value available
- Price/Book of 12.53 is very high
- Price/Sales of 7.05 indicates premium pricing
Future
65/100
Ref Growth rates
Positives
- 23.5% YoY revenue growth is strong
- Year-over-year EPS growth of +400% shows dramatic improvement
Watchpoints
- Earnings growth (YoY) is N/A, indicating instability
- Q/Q EPS growth is flat at 0.0%
Past
55/100
Ref Historical trends
Positives
- Recent quarters show positive earnings surprises (e.g., +100%, +76.5%)
- Progressing from deep losses to near-breakeven
Watchpoints
- Earnings history is volatile with multiple negative quarters
- Average surprise over last 4 quarters is -16.18%, indicating declining accuracy
Health
45/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 4.09 and quick ratio of 2.38 indicate strong liquidity
- Debt/Equity of 0.58 is below sector average of 2.89
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health
- ROE is negative at -1.91%
- No Altman Z-Score available for distress risk assessment
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield
- Dividend strength score of 0/100
- Payout ratio is 0.00% with no history of returns to shareholders
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$32.83
Analyst Target
$37.0
Upside/Downside
+12.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AXGN and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AXGN
Axogen, Inc.
Primary
|
+76.4% | +203.1% | +75.6% | +145.6% | +0.6% | +5.8% |
|
IOVA
Iovance Biotherapeutics, Inc.
Peer
|
-87.4% | -32.7% | +20.9% | +76.2% | -23.6% | +7.9% |
|
UFPT
UFP Technologies, Inc.
Peer
|
+289.1% | +40.8% | -5.7% | -1.3% | +5.3% | +1.4% |
|
NBTX
Nanobiotix S.A.
Peer
|
+91.8% | +705.8% | +855.9% | +12.8% | -6.4% | +5.6% |
|
GENB
Generate Biomedicines, Inc.
Peer
|
-8.8% | -8.8% | -8.8% | -8.8% | -5.6% | -16.1% |
AXG
Axogen, Inc.
Primary
5Y
+76.4%
3Y
+203.1%
1Y
+75.6%
6M
+145.6%
1M
+0.6%
1W
+5.8%
IOV
Iovance Biotherapeutics, Inc.
Peer
5Y
-87.4%
3Y
-32.7%
1Y
+20.9%
6M
+76.2%
1M
-23.6%
1W
+7.9%
UFP
UFP Technologies, Inc.
Peer
5Y
+289.1%
3Y
+40.8%
1Y
-5.7%
6M
-1.3%
1M
+5.3%
1W
+1.4%
NBT
Nanobiotix S.A.
Peer
5Y
+91.8%
3Y
+705.8%
1Y
+855.9%
6M
+12.8%
1M
-6.4%
1W
+5.6%
GEN
Generate Biomedicines, Inc.
Peer
5Y
-8.8%
3Y
-8.8%
1Y
-8.8%
6M
-8.8%
1M
-5.6%
1W
-16.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
65.88
PEG Ratio
N/A
P/B Ratio
12.53
P/S Ratio
7.05
EV/Revenue
7.21
EV/EBITDA
142.18
Market Cap
$1.51B
Profitability
Profit margins and return metrics
Profit Margin
-0.98%
Operating Margin
3.18%
Gross Margin
74.76%
ROE
-1.91%
ROA
1.21%
Growth
Revenue and earnings growth rates
Revenue Growth
+23.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.58
Moderate
Current Ratio
4.09
Strong
Quick Ratio
2.38
Excellent
Cash/Share
$0.78
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-24
$N/A
2025-10-29
$0.12
+76.5% surprise
2025-08-05
$0.12
+100.0% surprise
2025-05-08
$-0.02
-225.0% surprise
Healthcare Sector Comparison
Comparing AXGN against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-1.91%
This Stock
vs
-88.14%
Sector Avg
-97.8%
(Below Avg)
Profit Margin
-0.98%
This Stock
vs
-16.28%
Sector Avg
-94.0%
(Weaker)
Debt to Equity
0.58
This Stock
vs
2.66
Sector Avg
-78.3%
(Less Debt)
Revenue Growth
23.5%
This Stock
vs
124.04%
Sector Avg
-81.1%
(Slower)
Current Ratio
4.09
This Stock
vs
4.47
Sector Avg
-8.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AXGN
Axogen, Inc.
|
NEUTRAL | $1.51B | - | -1.9% | -1.0% | $32.83 | |
|
IOVA
Iovance Biotherapeutics, Inc.
|
NEUTRAL | $1.52B | - | -55.5% | -148.4% | $3.7 | Compare |
|
UFPT
UFP Technologies, Inc.
|
NEUTRAL | $1.53B | 22.71 | 17.8% | 11.3% | $198.68 | Compare |
|
NBTX
Nanobiotix S.A.
|
BEARISH | $1.54B | - | -% | -73.5% | $31.83 | Compare |
|
GENB
Generate Biomedicines, Inc.
|
BEARISH | $1.47B | - | -81.7% | -% | $11.53 | Compare |
AXGN
Axogen, Inc.
NEUTRAL
Mkt Cap
$1.5B
P/E
-
ROE
-1.9%
Price
$32.83
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-16 | WEILER KATHY JOHNSON | Director | Sale | 46,653 | $1,378,476 |
| 2025-12-16 | MCBRIDE-WENDELL AMY A. | Director | Sale | 43,684 | $1,280,465 |
| 2025-12-16 | WEILER KATHY JOHNSON | Director | Option Exercise | 40,073 | $280,150 |
| 2025-12-16 | MCBRIDE-WENDELL AMY A. | Director | Option Exercise | 43,684 | $301,963 |
| 2025-12-15 | HARTLEY LINDSEY MARIE | Chief Financial Officer | Sale | 14,812 | $442,294 |
| 2025-12-15 | HARTLEY LINDSEY MARIE | Chief Financial Officer | Option Exercise | 14,812 | $122,495 |
| 2025-12-11 | BEGAN MARC A. | General Counsel | Sale | 13,222 | $396,660 |
| 2025-12-10 | DALE MICHAEL D | Chief Executive Officer | Sale | 25,000 | $750,000 |
| 2025-12-09 | DEVINNEY ERICK WAYNE | Officer | Sale | 19,517 | $609,087 |
| 2025-12-09 | BEGAN MARC A. | General Counsel | Sale | 9,278 | $289,548 |
| 2025-12-09 | TYNDALL JOSEPH A | Director | Sale | 25,108 | $777,771 |
| 2025-12-09 | KEMP JENS SCHROEDER | Officer | Sale | 8,156 | $254,532 |
| 2025-12-09 | THOMAS PAUL G | Director | Sale | 21,399 | $633,710 |
| 2025-12-09 | DALE MICHAEL D | Chief Executive Officer | Sale | 61,463 | $1,918,137 |
| 2025-12-09 | JOHNSON JOHN H. | Director | Sale | 45,379 | $1,390,393 |
WEILER KATHY JOHNSON
Director
2025-12-16
46,653 shares
·
$1,378,476
MCBRIDE-WENDELL AMY A.
Director
2025-12-16
43,684 shares
·
$1,280,465
WEILER KATHY JOHNSON
Director
2025-12-16
40,073 shares
·
$280,150
MCBRIDE-WENDELL AMY A.
Director
2025-12-16
43,684 shares
·
$301,963
HARTLEY LINDSEY MARIE
Chief Financial Officer
2025-12-15
14,812 shares
·
$442,294
HARTLEY LINDSEY MARIE
Chief Financial Officer
2025-12-15
14,812 shares
·
$122,495
BEGAN MARC A.
General Counsel
2025-12-11
13,222 shares
·
$396,660
DALE MICHAEL D
Chief Executive Officer
2025-12-10
25,000 shares
·
$750,000
DEVINNEY ERICK WAYNE
Officer
2025-12-09
19,517 shares
·
$609,087
BEGAN MARC A.
General Counsel
2025-12-09
9,278 shares
·
$289,548
TYNDALL JOSEPH A
Director
2025-12-09
25,108 shares
·
$777,771
KEMP JENS SCHROEDER
Officer
2025-12-09
8,156 shares
·
$254,532
THOMAS PAUL G
Director
2025-12-09
21,399 shares
·
$633,710
DALE MICHAEL D
Chief Executive Officer
2025-12-09
61,463 shares
·
$1,918,137
JOHNSON JOHN H.
Director
2025-12-09
45,379 shares
·
$1,390,393
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
9 analysts
Canaccord Genuity
2025-12-05
Buy
Buy
HC Wainwright & Co.
2025-12-05
Buy
Buy
Jefferies
2025-12-04
Buy
Buy
Lake Street
2025-12-04
Buy
Buy
Mizuho
2025-12-01
Outperform
HC Wainwright & Co.
2025-10-30
Buy
Buy
Raymond James
2025-10-30
Outperform
Outperform
Canaccord Genuity
2025-10-30
Buy
Buy
Citizens
2025-10-30
Market Outperform
Market Outperform
HC Wainwright & Co.
2025-09-30
Buy
Past News Coverage
Recent headlines mentioning AXGN from our newsroom.
Newest → oldest
No matching news yet.